Plasma Tumor Necrosis Factor α Levels and the –238* A Promoter Polymorphism in Patients with Antiphospholipid Syndrome

Summary

Objectives. To explore the possible involvement of the proinflammatory and prothrombotic cytokine TNFα in APS by determining the plasma levels in patients and to test for association of TNFA promoter polymorphisms and HLA class II genotypes with both plasma TNF and disease. Patients and Method. We studied 83 Caucasoid patients with APS and two groups of healthy controls. TNFα levels were determined in plasma from 35 patients’ and 21 controls using a highly sensitive sandwich ELISA. The full patient group was genotyped together with 95 ethnically matched healthy controls. -308 and -238 TNFA promoter polymorphisms were assessed by ARMS-PCR. HLA-DQB1, DQA1 and DRB1 genotypes were determined by PCR using sequence specific primers. Results. TNFα levels were significantly higher in patients with APS than healthy controls (median 2.95 pg/ml [range 0.51-10.75] vs. 0.95 pg/ml [0.51-1.6], respectively; p = 0.0001). Frequencies of TNFA-308*2 genotype did not differ between patients and controls. In contrast, TNFA-238*A positive genotype was more frequent in APS patients with arterial thrombosis and pregnancy loss than in controls (OR 3.7 [95% CI 1.37-10.1], p = 0.007 and OR 3.95 [95% CI 1.3-11.7], p = 0.01; respectively). DQB1*0303-DRB1*0701 haplotype was associated with TNFA-238*A in the control group (OR 96.0 [95% CI 9.6-959], p 0.0001) as well as in APS patient’s group (OR 54.2 [95% CI 9.6-306.5], p 0.0001). Conclusions. Raised plasma TNFα levels were found in patients with APS. As a prothrombotic and proinflammatory cytokine, TNFα may be involved in the development of clinical features of APS. The lack of correlation between the TNFA-238 polymorphism and plasma levels associated with disease suggests that the TNFα genetic marker may only indirectly relate to protein levels by virtue of allelic association with a functional marker which may reside in the HLA class II region.

Keywords

TNFA - thrombosis - HLA - Haplotype

• References

• 1 Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
• 2 Dagenais P, Urowitz MB, Gladman DD, Norman CS. A family study of the antiphospholipid syndrome associated with other autoimmune diseases. J Rheumatol 1992; 19: 1393-6.
• 3 Wilson WA, Scopelitis E, Michalski JP, Pierangeli SS, Silveira LH, Elston RC, Harris EN. Familial anticardiolipin antibodies and C4 deficiency geno-types that coexist with MHC DQB1 risk factors. J Rheumatol 1995; 22: 227-35.
• 4 Bertolaccini ML, Atsumi T, Caliz AR, Amengual O, Khamashta MA, Hughes GR, Koike T. Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 2000; 43: 683-8.
• 5 Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992; 35: 124-5.
• 6 Camps MT, Cuadrado MJ, Ocon P, Alonso A, Gutierrez A, Guil M, Grana MI, de Ramon E. Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 1995; 4: 51-5.
• 7 Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52.
• 8 Goldfeld AE, Doyle C, Maniatis T. Human tumor necrosis factor alpha gene regulation by virus and lipopolysaccharide. Proc Natl Acad Sci USA 1990; 87: 9769-73.
• 9 Bendtzen K, Morling N, Fomsgaard A, Svenson M, Jakobsen B, Odum N, Svejgaard A. Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988; 28: 599-606.
• 10 Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-7.
• 11 Pociot F, Wilson AG, Nerup J, Duff GW. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J. Immunol 1993; 23: 3050-3.
• 12 McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-10.
• 13 Pociot FSDA, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNFα alpha gene promoter. Scand J Immunol 1995; 42: 501-4.
• 14 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
• 15 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
• 16 Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
• 17 Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with anti-phospholipid syndrome. Br J Rheumatol 1996; 35: 1239-43.
• 18 Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 1104-8.
• 19 Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G, Wordsworth P. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996; 23: 1725-8.
• 20 Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-60.
• 21 Lu LY, Ding WZ, Fici D, Deulofeut R, Cheng HH, Cheu CC, Sung PK, Schur PH, Fraser PA. Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus in Taiwan. Arthritis Rheum 1997; 40: 1138-45.
• 22 Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
• 23 Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993; 41: 119-34.
• 24 Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41: 205-14.
• 25 Wilson WA, Gharavi AE. Genetic risk factors for aPL syndrome. Lupus 1996; 5: 398-403.
• 26 Arnett FC, Olsen ML, Anderson KL, Reveille JD. Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest 1991; 87: 1490-5.
• 27 Caliz T, Atsumi T, Kondeatis E, Amengual O, Khamashta MA, Vaughan RV, Lanchbury JS, Hughes GRV. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 caucasoid patients. Rheumatology. (in press).
• 28 Arnett FC, Thiagarajan P, Ahn C, Reveille JD. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 1999; 42: 268-74.
• 29 Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-3.